Sugi Predict

Sugi Predict / Compounds / SCHEMBL16650545

SCHEMBL16650545

SCHEMBL16650545

COC(=O)c1cc2c(Br)cn(C)c(=O)c2s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.43
▸ HPGD P15428 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ CYP2C9 P11712 2/20 0.42
▸ CYP2C19 P33261 2/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ BRD4 O60885 3/20 0.41
▸ BRD9 Q9H8M2 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ PPARG P37231 1/20 0.40
▸ MAPK10 P53779 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ NCOR2 Q9Y618 1/20 0.40
▸ CSNK2A2 P19784 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ CSNK2B P67870 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22289951 0.90 BRD4 (0.46) ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2C9
SCHEMBL22859917 0.87 GPR35 (0.41) ALDH1A1SMN1; SMN2BRD4BRD9PKM
SCHEMBL21904966 0.85 TSHR (0.55) ALDH1A1SMN1; SMN2NPC1PKMKMT2A
SCHEMBL16650633 0.82 PIM2 (0.42) BRD4BRD9CSNK2A2KDRCSNK2B
SCHEMBL26654376 0.82 BRD4 (0.41) ALDH1A1CYP1A2CYP2C19BRD4BRD9
SCHEMBL21904828 0.80 BRD4 (0.47) BRD4KMT2ARXFP1
SCHEMBL22859926 0.80 KDM4E (0.46) ALDH1A1SMN1; SMN2BRD4BRD9RXFP1
SCHEMBL22859390 0.78 MAPT (0.51) ALDH1A1HPGDBRD4BRD9NPC1
SCHEMBL22289905 0.77 BRD4 (0.40) ALDH1A1HPGDSMN1; SMN2BRD4BRD9
SCHEMBL15203667 0.76 CSNK2A2 (0.49) ALDH1A1HPGDSMN1; SMN2NPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276978-A1 HETEROCYCLIC COMPOUNDS AS BET INHIBITORS SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2025-09-04 — — US disclosed
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 — — EP disclosed
CN-114286818-B Heterocyclic compounds as BET inhibitors 诺维逊生物股份有限公司 2024-09-20 — — CN disclosed
US-20240182490-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2024-06-06 — — US disclosed
US-11884680-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-01-30 — — US disclosed
US-20230339964-A1 HETEROCYCLIC COMPOUNDS AS BET INHIBITORS NUVATION BIO INC (US) 2023-10-26 — — US disclosed
US-20230339964-A1 HETEROCYCLIC COMPOUNDS AS BET INHIBITORS NUVATION BIO INC (US) 2023-10-26 — — US disclosed
US-20230339964-A1 HETEROCYCLIC COMPOUNDS AS BET INHIBITORS NUVATION BIO INC (US) 2023-10-26 — — US disclosed
US-11584756-B2 Heterocyclic compounds as BET inhibitors NUVATION BIO INC. (US) 2023-02-21 — — US disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
US-20150183784-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-07-02 — — US disclosed
US-20150183784-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-07-02 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
WO-2015058160-A1 BROMODOMAIN INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2015-04-23 — — WO disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
WO-2015058160-A1 BROMODOMAIN INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2015-04-23 — — WO disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584756-B2 Heterocyclic compounds as BET inhibitors BET1, BRD4, BRD3 ALDH1A1 4239/4885HPGD 2777/4885SMN1; SMN2 2600/4885
US-20250276978-A1 HETEROCYCLIC COMPOUNDS AS BET INHIBITORS BET1, BRD4, BRD3 ALDH1A1 4239/4885HPGD 2777/4885SMN1; SMN2 2600/4885
US-20240182490-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 ALDH1A1 3316/4885HPGD 1266/4885SMN1; SMN2 4410/4885
US-20150111885-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 ALDH1A1 3316/4885HPGD 1266/4885SMN1; SMN2 4410/4885
US-20230339964-A1 HETEROCYCLIC COMPOUNDS AS BET INHIBITORS BET1, BRD4, BRD3 ALDH1A1 4239/4885HPGD 2777/4885SMN1; SMN2 2600/4885
US-20150183784-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 ALDH1A1 3316/4885HPGD 1266/4885SMN1; SMN2 4410/4885
US-11884680-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 ALDH1A1 3316/4885HPGD 1266/4885SMN1; SMN2 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.